An FDA advisory committee's evaluation of Fabre-Kramer Pharmaceuticals Inc.'s investigational antidepressant gepirone may turn on a question of interest to the broader pharmaceutical industry: How should the requirement for substantial evidence of effectiveness be interpreted when there are multiple negative or failed trials along with positive ones?
The Psychopharmacologic Drugs Advisory Committee will meet Dec. 1 to discuss the efficacy and safety data for gepirone hydrochloride extended-release...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?